Emergency Field Trips Sample Clauses

Emergency Field Trips. 1. There will be an Emergency Field Trip list. Emergency field trips are trips that are called in on the day the trip is scheduled or are called in after 5:00 P.M. the night before the scheduled field trip for whatever reason. 2. The Transportation Supervisor will call the first Bus Driver according to where the pin is located on the Emergency Field Trip list. If that Bus Driver refuses the field trip, the Transportation Supervisor will continue to follow the Emergency Field Trip List that lists Bus Drivers by classification seniority. The pin shall rotate continuously. 3. When a Bus Driver does an Emergency Field Trip, this field trip is not charged against other field trips. 4. If an Emergency Field Trip is canceled after the Bus Driver has been selected, the pin remains on the selected Bus Driver’s name.
Sample 1Sample 2Sample 3See All (8)
AutoNDA by SimpleDocs
Emergency Field Trips. 1. After regular field trips are assigned, a list of emergency field trips is generated. A list of all known emergency trips will be posted by 5:00 a.m. the day prior to the trip. The dispatcher will put an “emergency trip notification” on the time card of eligible drivers. Response is due by 7:00 a.m. 2. The eligible drivers then sign the emergency field trip list stating their preference(s) for the trip(s). Drivers may bid on a regular and emergency field trip as long as the two trips do not conflict. 3. The trip(s) are awarded in the order of the emergency list, not seniority order. 4. Eligible drivers who do not state a preference by signing the emergency field trip list shall be passed on the appropriate rotation list as though they performed the assignment. 5. In the event that trips remain to be filled, three (3) verified radio calls will be made in seniority order to all eligible drivers. Drivers reached may choose to switch assignments, even if already assigned a trip, if the two trips are compatible. Drivers who cannot be reached shall be passed over in the appropriate rotation list as though they performed the assignment. Drivers absent from work on the day of the notification will not be contacted. For emergency field trips which occur during Winter and Spring Break one (1) documented telephone call will be made to the telephone number on record. 6. When an emergency field trip is posted, the successful bidder shall be guaranteed two (2) hours pay. The guarantee may be for two consecutive hours or split as a take and return with each portion as a one hour minimum for a total of two hours. 7. Estimated ending times will be posted when that information is available to Transportation, however, ending times are not guaranteed and pay will be for actual time worked or the 2-hour guarantee, whichever is greater. 8. When extra driver(s) are needed for weekend trips that are requested after 5:00 on Friday, drivers will be contacted in order of the emergency list. If a driver cannot be reached or cannot take the trip, they will remain on the emergency list and eligible for the next emergency trip posted. 9. Times are subject to change depending on customer demand. When bidding on a trip, driver is expected to complete the trip. If an awarded trip is canceled before the driver reports for the trip, the driver will be eligible to bid the next available posting in order of seniority. If the driver reports for an awarded trip and it is canceled prior to lea...
Sample 1Sample 2Sample 3See All (5)
Emergency Field Trips. 1. A daily list of emergency field trips is generated. 2. The emergency field trip seniority list is reviewed in order to determine which drivers are in turn for the trips. 3. The eligible drivers are notified of the available emergency trips. 4. The eligible drivers then sign the emergency field trip list stating their preference(s) for the trips. 5. The trip(s) are awarded in seniority order. 6. Eligible drivers who do not state a preference by signing the emergency field trip list shall be passed on the appropriate rotation list as though they performed the assignment. 7. In the event that trips remain to be filled, three (3) verified radio calls will be made in seniority order to all eligible drivers. Drivers who cannot be reached shall be passed over in the appropriate rotation list as though they performed the assignment. Drivers absent from work on the day of the notification will not be contacted. For emergency field trips which occur during Winter and Spring Break one (1) documented telephone call will be made to the telephone number of record. 8. When management decides to post a regular field trip or an emergency field trip, the successful bidder shall be guaranteed two
Sample 1Sample 2
Emergency Field Trips. Any field trip given to the transportation supervisor to be run within twenty-four (24) hours.
Sample 1

Related to Emergency Field Trips

  • Field Trips Orange COUNTY funds may not be used to support any overnight and/or out of Central Florida travel, unless approved by the COUNTY’S Manager of the CCC or designee in advance. The AGENCY must have on file for field trip(s) that each participant, adult or minor, must have a signed release of liability form releasing the COUNTY from any liability. If the participant is a minor, the release must be signed by a parent/guardian. Central Florida is defined as Orange, Osceola, Seminole, Brevard, Lake, Polk, and Volusia Counties.

  • Field The term “

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!